RESUMO
A total of 1,122 patients with various hemopoietic disorders were transplanted at the Princess Margaret Hospital since 1970. The majority suffered from acute or chronic myeloid leukemia. Improvements in support strategies permitted a gradual escalation of the upper age limit for transplant candidates and resulted in better survival. The overall survival at 10 years of all patients transplanted consecutively either before or after 1986 increased from 30 to 50%. This change was observed independent of other transplant related risk factors and is predominantly attributable to the use of cyclosporine and ganciclovir. An improvement of similar magnitude was seen for transplant recipients presenting with good risk features. The 10-year survival of patients with acute and chronic myeloid leukemia transplanted from a fully matched sibling donor in first complete remission or first chronic phase increased from 40 to approximately 70%. The quality of life of surviving patients may not return to normal but appears to improve with time after the transplant.
Assuntos
Transplante de Medula Óssea/estatística & dados numéricos , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Leucemia Mieloide Aguda/terapia , Transplante de Medula Óssea/mortalidade , Transplante de Medula Óssea/fisiologia , Causas de Morte , Seguimentos , Sobrevivência de Enxerto , Células-Tronco Hematopoéticas/citologia , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/radioterapia , Leucemia Mieloide Aguda/radioterapia , Segunda Neoplasia Primária/epidemiologia , Ontário , Cuidados Paliativos , Complicações Pós-Operatórias/classificação , Complicações Pós-Operatórias/epidemiologia , Qualidade de Vida , Estudos Retrospectivos , Medição de Risco , Taxa de Sobrevida , Fatores de Tempo , Transplante Homólogo , Resultado do Tratamento , Irradiação Corporal TotalRESUMO
Small-angle X-ray scattering measurements on native pig thyroglobulin in phosphate buffer, pH6.9, yield a radius of gyration of 6.4nm (64A), a particle volume of approx. 1.5x10(3)nm(3) (1.5x10(6)A(3)), an axial ratio of 2.2:1 (assuming an ellipsoidal shape), and a solvation of 0.63g of solvent/g of protein.
